Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$4.01M-$4.01MN/M vs Q3 2021 EPS Diluted-$0.07-$0.07N/M vs Q3 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
-$4,010,823
N/M
Operating Cash Flowderived-$53,268N/M ended Sep 30, 2022 · filed Nov 21, 2022 · 52 d after period end